Literature DB >> 7336

Investigations to characterize a new anti-arrhythmic drug, ORG 6001 including a simple test for calcium antagonism.

L A Salako, V Williams, J H Wittig.   

Abstract

1 The compound Org 6001 (3alpha-amino-2beta-hydroxy-5alpha-androstan-17-one hydrochloride) was found in recent experiments to exhibit anti-arrhythmic activity. Evidence is presented in this paper concerning its mode of action. 2 Org 6001 was 1.8 times more potent than procaine as a local anaesthetic on desheathed frog nerve. 3 Org 6001 had no effect on the resting potential of isolated cardiac muscle of rabbit, but greatly reduced the maximum rate of depolarization tion (MRD). The action potential duration TAPD) WAS MARGINALLY PROLONGED IN ATRIAL AND VENTRICULAR MUSCLE. 4 Org 6001 preferentially shortened APD in that part of the Purkinje system in which APD is normally longer than elsewhere, so that APD

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 7336      PMCID: PMC1667102          DOI: 10.1111/j.1476-5381.1976.tb07475.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  19 in total

1.  Antiarrhythmic, haemodynamic and metabolic effects of 3alpha-amino-5alpha-androstan-2beta-ol-17-one hydrochloride in greyhounds following acute coronary artery ligation.

Authors:  R J Marshall; J R Parratt
Journal:  Br J Pharmacol       Date:  1975-11       Impact factor: 8.739

2.  NONUNIFORM RECOVERY OF EXCITABILITY IN VENTRICULAR MUSCLE.

Authors:  J HAN; G K MOE
Journal:  Circ Res       Date:  1964-01       Impact factor: 17.367

3.  The effect of the cardiac membrane potential on the rapid availability of the sodium-carrying system.

Authors:  S WEIDMANN
Journal:  J Physiol       Date:  1955-01-28       Impact factor: 5.182

4.  Antifibrillatory action.

Authors:  L Szekeres; E M Williams
Journal:  J Physiol       Date:  1962-03       Impact factor: 5.182

5.  ORG 6001 (3alpha-amino-5alpha-androstan-2beta-ol-17-one hydrochloride), a steroidal anti-arrhythmic agent.

Authors:  B B Vargaftig; M F Sugrue; W R Buckett; H van Riezen
Journal:  J Pharm Pharmacol       Date:  1975-09       Impact factor: 3.765

6.  Monophasic action potential and sinus rhythm stability after conversion of atrial fibrillation.

Authors:  S B Olsson; S Cotoi; E Varnauskas
Journal:  Acta Med Scand       Date:  1971-11

7.  The effect of experimental cardiac arrhythmias of a new anticonvulsant agent, Kö 1173, and its comparison with phenytoin and procainamide.

Authors:  J D Allen; J M Kofi; R G Shanks; S A Zaidi
Journal:  Br J Pharmacol       Date:  1970-05       Impact factor: 8.739

8.  The mode of action of quinidine on isolated rabbit atria interpreted from intracellular potential records.

Authors:  E M VAUGHAN WILLIAMS
Journal:  Br J Pharmacol Chemother       Date:  1958-09

9.  A comparison of tests for antifibrillatory action.

Authors:  E M WILLIAMS; L SZEKERES
Journal:  Br J Pharmacol Chemother       Date:  1961-12

10.  The effects on cardiac muscle and nerve of a fluorinated decahydroquinoline derivative, L7810, rapidly absorbed after oral administration.

Authors:  E E Bagwell; P Polster; E M Williams
Journal:  Br J Pharmacol       Date:  1973-06       Impact factor: 8.739

View more
  16 in total

1.  Comparative effects of a new orally active antidysrhythmic agent, Organon 6001, on the cardiac action potential of human ventricular muscle and sheep Purkinje fibres [proceedings].

Authors:  K A Kane
Journal:  Br J Pharmacol       Date:  1977-11       Impact factor: 8.739

2.  The site of gating in the ventricular conducting system of rabbit, dog and monkey hearts.

Authors:  P Gautier; E Coraboeuf
Journal:  Experientia       Date:  1980-04-15

3.  Effects of antiarrhythmic drugs on ventricular fibrillation thresholds of normal and ischaemic myocardium in the anaesthetized rat.

Authors:  R J Marshall; A W Muir; E Winslow
Journal:  Br J Pharmacol       Date:  1983-01       Impact factor: 8.739

4.  Voltage- and time-dependent depression of maximum rate of depolarization of guinea-pig ventricular action potentials by two steroidal antiarrhythmic drugs, CCI 22277 and ORG 6001.

Authors:  T J Campbell
Journal:  Br J Pharmacol       Date:  1982-11       Impact factor: 8.739

5.  The antidysrhythmic aminosteroid, ORG 6001, reduces the ST-segment elevation produced by coronary occlusion in the dog.

Authors:  R J Marshall; J R Parratt
Journal:  Br J Pharmacol       Date:  1977-10       Impact factor: 8.739

6.  Evaluation of antagonism of aconitine-induced dysrhythmias in mice as a method of detecting and assessing antidysrhythmic activity.

Authors:  E Winslow
Journal:  Br J Pharmacol       Date:  1980       Impact factor: 8.739

7.  Effects on rabbit nodal, atrial, ventricular and Purkinje cell potentials of a new antiarrhythmic drug, cibenzoline, which protects against action potential shortening in hypoxia.

Authors:  J S Millar; E M Vaughan Williams
Journal:  Br J Pharmacol       Date:  1982-03       Impact factor: 8.739

8.  Development of a severe model of early coronary artery ligation-induced dysrhythmias in the anaesthetized rat.

Authors:  R J Marshall; A W Muir; E Winslow
Journal:  Br J Pharmacol       Date:  1981-08       Impact factor: 8.739

9.  Electrophysiological and other effects on rabbit hearts of CCI22277, a new steroidal antiarrhythmic drug.

Authors:  T J Campbell; E M Vaughan Williams
Journal:  Br J Pharmacol       Date:  1982-06       Impact factor: 8.739

10.  An investigation into the characteristics of reperfusion-induced arrhythmias in the anaesthetized rat and their susceptibility to antiarrhythmic agents.

Authors:  K A Kane; J R Parratt; F M Williams
Journal:  Br J Pharmacol       Date:  1984-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.